Plasma pharmacokinetics, nervous system biodistribution and biostability, and spinal cord permeability at the blood-brain barrier of putrescine-modified catalase in the adult rat

Experimental Neurology

Volumn 159, Issue 1, 1999, Pages 191-203

  Reinholz, Monica M ^a   Haggard, Jill J ^a   Curran, Geoffry L ^a   Poduslo, Joseph F ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antioxidant; Blood brain barrier; Catalase; Permeability; Putrescine

Indexed keywords

CATALASE; FREE RADICAL; PUTRESCINE;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DEGENERATIVE DISEASE; DRUG DISTRIBUTION; DRUG STABILITY; ENZYME ACTIVITY; ENZYME MODIFICATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SPINAL CORD; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032826921     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1999.7117     Document Type: Article

References (62)

1. Acworth I. N., Phil D., Bailey B. Reactive oxygen species. The Handbook of Oxidative Metabolism. 1995;ESA Inc. Chelmsford. p. 2.1-2.4.
2. Adams D. H., Burgess E. H. The effect of the degree of homogenization on the catalase activity of liver "homogenates" Br. J. Cancer. 11:1957;310-325.
3. Bains J. S., Shaw C. A. Neurodegeneration disorders in humans: The role of glutathione in oxidative stress-mediated neuronal death. Brain Res. Rev. 25:1997;335-358.
4. Banks W. A., Kastin A. J., Huang W., Jaspan J. B., Maness L. M. Leptin enters the brain by a saturable system independent of insulin. Peptides. 17:1996;305-311.
5. Brown R. H. Amyotrophic lateral sclerosis: Recent insights from genetics and transgenic mice. Cell. 80:1995;687-692.
6. Brown R. H. Superoxide dismutase and familial amyotrophic lateral sclerosis: New insights into mechanisms and treatments. Ann. Neurol. 39:1996;145-146.
7. Calabrese E. J., Canada A. T. Catalase: Its role in xenobiotic detoxification. Pharmacol. Ther. 44:1989;297-307.
8. Chan P. H. Role of oxidants in ischemic brain damage. Stroke. 27:1996;1124-1129.
9. Chance B., Herbert D. The enzyme-substrate compounds of bacterial catalase and peroxides. Biochem. J. 46:1950;402-414.
10. Chance B., Maehly A. C. Assay of catalases and peroxidases. Methods Enzymol. 2:1955;764-775.
11. Chance B., Oshino N. Kinetics and mechanisms of catalase in peroxisomes of the mitochondrial fraction. Biochem. J. 122:1971;225-233.
12. Coyle J. T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
13. Cohen G., Dembiec D., Marcus J. Measurement of catalase activity in tissue extracts. Anal. Biochem. 34:1970;30-38.
14. Deduve C. Biochemical studies on the occurrence, biogenesis, and life history of mammalian peroxisomes. J. Histochem. Cytochem. 21:1973;941-948.
15. Deisseroth A., Dounce A. Catalase: Physical and chemical properties, mechanisms of catalysis, and physiological role. Physiol. Rev. 50:1970;319-375.
16. Epstein C. J., Chan P. H., Cadet J. L. Cu,Zn-superoxide dismutase transgenic mice in the study of the role of oxidative stress in neurodegenerative disorders. Neurodegenerative Disease. 1994;Academic Press, San Diego. p. 239-252.
17. Ferrante R. J., Browne S. E., Shinobu L. A., Bowling A. C., Baik M. J., Macgarvey U., Kowall N. W., Brown R. H., Beal M. F. Evidence for increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 69:1997;2064-2074.
18. Gotz M. E., Kunig G., Reiderer P., Youdim M. H. Oxidative stress: Free radical production in neural degeneration. Pharmacol. Ther. 63:1994;37-122.
19. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 59:1992;1609-1623.
20. Halliwell B., Gutteridge J. M. C., Cross C. E. Free radicals, antioxidants, and human disease: Where are we now. J. Lab. Clin. Med. 119:1992;598-620.
21. Ikeda Y., Long D. M. The molecular basis of brain injury and brain edema: The role of oxygen free radicals. Neurosurgery. 27:1990;1-11.
22. Ikeda K., Kinoshita M., Iwasaki Y., Tagaya N., Shijima T. Lectinized superoxide dismutase retards wobbler mouse motorneuron disease. Neuromusc. Dis. 5:1995;383-390.
23. Jenner P. Oxidative stress in Parkinson's disease and other neurodegenerative disorders. Pathol. Biol. 44:1996;57-64.
24. Johansson L. H., Borg L. A. H. Spectrophotometric method for determination of catalase activity in small tissue samples. Anal. Biochem. 174:1988;331-336.
25. Jolly S. R., Kane W. J., Bailie M. B., Abrams G. D., Lucchesi B. R. Canine myocardial reperfusion injury: Its reduction by the combined administration of superoxide dismutase and catalase. Circ. Res. 54:1984;277-284.
26. Julka D., Pal R., Gill K. D. Neurotoxicity of Dichlorvos: Effect on antioxidant defense system in the rat central nervous system. Exp. Mol. Pathol. 56:1992;144-152.
27. Kelly K., Boux H., Petkau A., Sehon A. On the safety of treatment with bovine superoxide dismutase: Production of humoral antibody response in rabbits with repeated treatment. Can. J. Physiol. Pharmacol. 60:1982;1374-1381.
28. Kim S. M., Kang J. H. Peroxidatic activity of human Cu, Zn-superoxide dismutase. Mol. Cells. 7:1997;120-124.
29. Kinouchi H., Epstein C. J., Mizui T., Carlson E., Chen S. F., Chan P. H. Attenuation of focal cerebral ischemic injury in transgenic mice over-expressing CuZn superoxide dismutase. Proc. Natl. Acad. Sci. USA. 88:1991;11158-11162.
30. Liu T. H., Beckman J. S., Freeman B. A., Hogan E. L., Hsu C. Y. Polyethylene glycol-conjugated superoxide dismutase and catalase reduce ischemic brain injury. Am. J. Physiol. 256:1989;H589-H593.
31. Liu D. The roles of free radicals in amyotrophic lateral sclerosis. J. Mol. Neurosci. 7:1996;159-167.
32. Mao G. D., Thomas P. D., Lopaschuk G. D., Poznansky M. J. Superoxide dismutase (SOD)-catalase conjugates: Role of hydrogen peroxide and the Fenton reaction in sod toxicity. J. Biol. Chem. 268:1993;416-420.
33. Markland S. L., Westman N. G., Lundgren E., Roos G. Copper- and zinc-containing superoxide dismutase, manganese-containing superoxide dismutase, catalase, and glutathione peroxidase in normal and neoplastic human cell lines and normal human tissues. Cancer Res. 42:1982;1955-1961.
34. Multhaup G., Ruppert T., Schlicksupp A., Hesse L., Beher D., Masters C. L., Beyreuther K. Reactive oxygen species and Alzheimer's disease. Biochem. Pharmacol. 54:1997;533-539.
35. Olanow C. W. An introduction to the free radical hypothesis in Parkinson's disease. Ann. Neurol. 32:1992;S2-S9.
36. Olanow C. W. A radical hypothesis for neurodegeneration. Trends Neurosci. 16:1993;439-444.
37. Orr W. C., Sohals R. S. Extension of lifespan by over-expression of superoxide dismutase and catalase in Drosophila melanogaster. Science. 263:1994;1128-1130.
38. Pan W. H., Banks W. A., Kastin A. J. Blood-brain barrier permeability to ebiratide and TNF in acute spinal cord injury. Exp. Neurol. 146:1997;367-373.
39. Parkes T. L., Elia A. J., Dickenson D., Hilliker A. J., Phillips J. P., Boulianne G. L. Extension of Drosophila lifespan by over-expression of human SOD1 in motorneurons. Nature Genet. 19:1998;171-174.
40. Percy M. E. Catalase: An old enzyme with a new role. Can. J. Biochem. Cell. Biol. 62:1984;1006-1014.
41. Poduslo J. F., Curran G. L. Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy. Proc. Natl. Acad. Sci. USA. 89:1992;2218-2222.
42. Poduslo J. F., Curran G. L. Glycation increases the permeability of proteins across the blood nerve and blood brain barriers. Mol. Brain Res. 23:1994;157-162.
43. Poduslo J. F., Curran G. L., Berg C. T. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc. Natl. Acad. Sci. USA. 9:1994;5705-5709.
44. Poduslo J. F., Curran G. L. Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers. J. Neurochem. 66:1996;1599-1609.
45. Poduslo J. F., Curran G. L. Increased permeability of superoxide dismutase at the blood-nerve and blood-brain barriers with retained enzymatic activity after covalent modification with the naturally occurring polyamine, putrescine. J. Neurochem. 67:1996;734-741.
46. Poduslo J. F., Curran G. L., Gill J. S. Putrescine-modified nerve growth factor: Bioactivity, plasma pharmacokinetics, blood-brain/nerve barrier permeability, and nervous system biodistribution. J. Neurochem. 71:1998;1651-1660.
47. Poduslo J. F., Curran G. L., Kumar A., Frangione B., Soto C. β-Sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma. J. Neurobiol. 39:1999;371-382.
48. Reid T. J. III, Murthy M. R. N., Sicignano A., Tanaka N., Musick W. D. L., Rossman M. G. Structure and heme environment of beef liver catalase at 2.5 A resolution. Proc. Natl. Acad. Sci. USA. 78:1981;4767-4771.
49. Reinholz M. M., Merkle C. J., Poduslo J. F. Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis. Exp. Neurol. 159:1999;204-216.
50. Reveillaud I., Kongpachith R., Park R., Fleming J. E. Stress resistance of Drosophila transgenic for bovine CuZn superoxide dismutase. Free Rad. Res. Commun. 17:1992;73-85.
51. Richardson J. S. Free radicals in the genesis of Alzheimer's disease. Ann. N. Y. Acad. Sci. 695:1993;73-76.
52. Sendtner M., Thoenen H. Oxidative stress and motor neuron disease. Curr. Biol. 4:1994;1036-1039.
53. Scott M. D., Lubin B., Zuo L., Kuypers F. A. Erythrocyte defense against hydrogen peroxide: Preeminent importance of catalase. J. Lab. Clin. Med. 118:1991;7-16.
54. Smith P. K., Krohn R. I., Hermanson G. T., Mallia A. K., Gartner F. H., Provenzano M. D., Fujimoto E. K., Goeke N. M., Olson B. J., Klenk D. C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:1985;76-85.
55. Tanford C., Lovrien R. Dissociation of catalase into subunits. J. Am. Chem. Soc. 84:1962;1892-1896.
56. Tu P-H., Gurney M. F., Julien J-P., Lee V. M.-Y., Trojanowski J. Q. Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. Lab. Invest. 76:1997;441-456.
57. Wang P., Chen H., Qin H., Sankarapandi S., Becher M. W., Wong P., Zweier J. L. Over-expression of human copper, zinc-superoxide dismutase (SOD1) prevents postischemic injury. Proc. Natl. Acad. Sci. USA. 95:1998;4556-4560.
58. Weerasuriya A., Curran G. L., Poduslo J. F. Blood-nerve transfer of albumin and its implications for the endoneurial microenvironment. Brain Res. 494:1989;114-121.
59. Wengenack T. M., Curran G. L., Olson E. E., Poduslo J. F. Putrescine-modified catalase with preserved enzymatic activity exhibits increased permeability at the blood-nerve and blood-brain barriers. Brain Res. 767:1997;128-135.
60. Wengenack T. M., Curran G. L., Poduslo J. F. Postischemic, systemic administration of polyamine-modified superoxide dismutase reduces hippocampal CA1 neurodegeneration in rat global cerebral ischemia. Brain Res. 754:1997;46-54.
61. Yasmineh W. G., Theologides A. Catalase as a roving scavenger of hydrogen peroxide: A hypothesis. J. Lab. Clin. Med. 122:1993;110-114.
62. Yu B. P. Cellular defenses against damage from reactive oxygen species. Physiol. Rev. 74:1994;139-162.